120 related articles for article (PubMed ID: 29246820)
41. Hematopoietic progenitor cell mobilization and harvesting in children with malignancies: do the advantages of pegfilgrastim really translate into clinical benefit?
Merlin E; Zohar S; Jérôme C; Veyrat-Masson R; Marceau G; Paillard C; Auvrignon A; Le Moine P; Gandemer V; Sapin V; Halle P; Boiret-Dupré N; Chevret S; Deméocq F; Dubray C; Kanold J
Bone Marrow Transplant; 2009 Jun; 43(12):919-25. PubMed ID: 19104490
[TBL] [Abstract][Full Text] [Related]
42. Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs.
Ria R; Gasparre T; Mangialardi G; Bruno A; Iodice G; Vacca A; Dammacco F
Bone Marrow Transplant; 2010 Feb; 45(2):277-81. PubMed ID: 19584820
[TBL] [Abstract][Full Text] [Related]
43. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation.
Kröger N; Renges H; Krüger W; Gutensohn K; Löliger C; Carrero I; Cortes L; Zander AR
Br J Haematol; 2000 Dec; 111(3):761-5. PubMed ID: 11122135
[TBL] [Abstract][Full Text] [Related]
44. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation.
Bence-Bruckler I; Bredeson C; Atkins H; McDiarmid S; Hamelin L; Hopkins H; Perry G; Genest P; Huebsch L
Bone Marrow Transplant; 1998 Nov; 22(10):965-9. PubMed ID: 9849693
[TBL] [Abstract][Full Text] [Related]
45. Ancestim (recombinant human stem cell factor, SCF) in association with filgrastim does not enhance chemotherapy and/or growth factor-induced peripheral blood progenitor cell (PBPC) mobilization in patients with a prior insufficient PBPC collection.
da Silva MG; Pimentel P; Carvalhais A; Barbosa I; Machado A; Campilho F; Sousa SR; Miranda N; da Costa FL; Campos A; Vaz CP; Antas J; Passos-Coelho JL
Bone Marrow Transplant; 2004 Oct; 34(8):683-91. PubMed ID: 15322567
[TBL] [Abstract][Full Text] [Related]
46. Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma.
Hosing C; Qazilbash MH; Kebriaei P; Giralt S; Davis MS; Popat U; Anderlini P; Shpall EJ; McMannis J; Körbling M; Champlin RE
Br J Haematol; 2006 Jun; 133(5):533-7. PubMed ID: 16681642
[TBL] [Abstract][Full Text] [Related]
47. Lenograstim 5 µg/kg is not superior to biosimilar filgrastim 10 µg/kg in lymphoma patients undergoing peripheral blood stem cell mobilization after chemotherapy: preliminary results from a prospective randomized study.
Marchesi F; Vacca M; Giannarelli D; Ipsevich F; Pandolfi A; Gumenyuk S; Renzi D; Palombi F; Pisani F; Romano A; Spadea A; Papa E; Canfora M; Pierelli L; Mengarelli A
Transfusion; 2018 May; 58(5):1143-1148. PubMed ID: 29446445
[TBL] [Abstract][Full Text] [Related]
48. Pegfilgrastim compared with Filgrastim after autologous hematopoietic peripheral blood stem cell transplantation.
Vanstraelen G; Frère P; Ngirabacu MC; Willems E; Fillet G; Beguin Y
Exp Hematol; 2006 Mar; 34(3):382-8. PubMed ID: 16543072
[TBL] [Abstract][Full Text] [Related]
49. Feasibility and kinetics of CD34
Takhar H; Mislang AR; Singhal N; Brown MP
Asia Pac J Clin Oncol; 2017 Feb; 13(1):79-86. PubMed ID: 27649817
[TBL] [Abstract][Full Text] [Related]
50. Single-dose pegfilgrastim is comparable to daily filgrastim in mobilizing peripheral blood stem cells: a case-matched study in patients with lymphoproliferative malignancies.
Putkonen M; Rauhala A; Pelliniemi TT; Remes K
Ann Hematol; 2009 Jul; 88(7):673-80. PubMed ID: 19139894
[TBL] [Abstract][Full Text] [Related]
51. A prospective randomized trial of two popular mononuclear cell collection sets for autologous peripheral blood stem cell collection in multiple myeloma.
Cooling L; Hoffmann S; Herrst M; Muck C; Armelagos H; Davenport R
Transfusion; 2010 Jan; 50(1):100-19. PubMed ID: 19719472
[TBL] [Abstract][Full Text] [Related]
52. Phase I trial of parathyroid hormone to facilitate stem cell mobilization.
Ballen KK; Shpall EJ; Avigan D; Yeap BY; Fisher DC; McDermott K; Dey BR; Attar E; McAfee S; Konopleva M; Antin JH; Spitzer TR
Biol Blood Marrow Transplant; 2007 Jul; 13(7):838-43. PubMed ID: 17580262
[TBL] [Abstract][Full Text] [Related]
53. Peripheral blood stem cell mobilization and engraftment after autologous stem cell transplantation with biosimilar rhG-CSF.
Reményi P; Gopcsa L; Marton I; Réti M; Mikala G; Pető M; Barta A; Bátai A; Farkas Z; Borbényi Z; Csukly Z; Bodó I; Fábián J; Király A; Lengyel L; Piukovics K; Torbágyi E; Masszi T
Adv Ther; 2014 Apr; 31(4):451-60. PubMed ID: 24687301
[TBL] [Abstract][Full Text] [Related]
54. Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma.
Fruehauf S; Klaus J; Huesing J; Veldwijk MR; Buss EC; Topaly J; Seeger T; Zeller LW; Moehler T; Ho AD; Goldschmidt H
Bone Marrow Transplant; 2007 Jun; 39(12):743-50. PubMed ID: 17450182
[TBL] [Abstract][Full Text] [Related]
55. Efficient peripheral blood stem cell mobilization with low-dose G-CSF (50 microg/m2) after salvage chemotherapy for lymphoma.
Martínez C; Sureda A; Martino R; Cancelas JA; Madoz P; García J; Brunet S
Bone Marrow Transplant; 1997 Nov; 20(10):855-8. PubMed ID: 9404926
[TBL] [Abstract][Full Text] [Related]
56. Intermediate-dose Ara-C plus G-CSF for stem cell mobilization in patients with lymphoid malignancies, including predicted poor mobilizers.
Giebel S; Kruzel T; Czerw T; Sadus-Wojciechowska M; Najda J; Chmielowska E; Grosicki S; Jurczyszyn A; Pasiarski M; Nowara E; Glowala-Kosinka M; Chwieduk A; Mitrus I; Smagur A; Holowiecki J
Bone Marrow Transplant; 2013 Jul; 48(7):915-21. PubMed ID: 23292239
[TBL] [Abstract][Full Text] [Related]
57. Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients.
Martino M; Praticò G; Messina G; Irrera G; Massara E; Messina G; Console G; Iacopino P
Eur J Haematol; 2006 Nov; 77(5):410-5. PubMed ID: 16930141
[TBL] [Abstract][Full Text] [Related]
58. Pegfilgrastim compared with filgrastim for cytokine-alone mobilization of autologous haematopoietic stem and progenitor cells.
Herbert KE; Gambell P; Link EK; Mouminoglu A; Wall DM; Harrison SJ; Ritchie DS; Seymour JF; Prince HM
Bone Marrow Transplant; 2013 Mar; 48(3):351-6. PubMed ID: 22858510
[TBL] [Abstract][Full Text] [Related]
59. Paclitaxel and filgrastim for hematopoietic progenitor cell mobilization in patients with hematologic malignancies after failure of a prior mobilization regimen.
McKibbin T; Burzynski J; Greene R; Ochoa-Bayona J; Tsai TW; Callander N; Freytes C
Leuk Lymphoma; 2007 Dec; 48(12):2360-6. PubMed ID: 18067011
[TBL] [Abstract][Full Text] [Related]
60. Mobilization with cyclophosphamide reduces the number of lymphocyte subpopulations in the leukapheresis product and delays their reconstitution after autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
Skerget M; Skopec B; Zontar D; Cernelc P
Radiol Oncol; 2016 Dec; 50(4):402-408. PubMed ID: 27904448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
